About Dr. Srikanth M
Dr. Srikanth M is a highly accomplished Senior Consultant Hematologist and Hemato-Oncologist with over two decades of global experience in diagnosing and treating complex blood disorders. He specializes in the management of hematological malignancies, including leukemia, lymphoma, and myeloma, as well as bone marrow transplantation. With extensive training and practice at premier institutions in the United Kingdom, he brings advanced expertise in targeted therapies and stem cell research to his clinical practice.
OPD Schedule Of Dr. Srikanth M
Consultation Fees Rs. 1500 /-
Apollo Hospitals, Greams Road, Chennai
Qualifications & Credentials
- MD (Research) - University College London, UK (2011)
- MBBS - Kasturba Medical College, Manipal Academy of Higher Education (1996)
- FRCPath (Haematology) - Royal College of Pathologists, UK (2006)
- CCT (Certificate of Completion of Training) in Haematology - PMETB, UK (2008)
- Fellowship in Hematology - Royal Marsden Hospital, UK
- MRCP (UK) - Royal College of Physicians, London (2000)
- Diploma in Clinical Pathology (Dip RCPath) - Royal College of Pathologists, UK
Areas of Expertise
- Multiple Myeloma
- Acute and Chronic Leukemias
- Non-Hodgkin and Hodgkin Lymphoma
- Aplastic Anemia
- Myelodysplastic Syndromes (MDS)
- Thalassemia and Hemoglobinopathies
- Immune Thrombocytopenic Purpura (ITP)
- Coagulation and Clotting Disorders
- Autologous Bone Marrow Transplantation
- Allogeneic Stem Cell Transplantation
- Chemotherapy and Immunotherapy Administration
- Targeted Therapy for Blood Cancers
- Bone Marrow Aspiration and Biopsy
- Chelation Therapy
- Management of Hemophilia
List of Disease and Treatment for which Dr. Srikanth M can be consulted
Professional Experience
Senior Consultant - Hematology and Hemato-Oncology, Apollo Hospitals, Greams Road, Chennai
Past Experience- Consultant Hematologist, Royal Marsden Hospital, London, UK
- Consultant, St George's Healthcare NHS Trust, London, UK
- Consultant, Hammersmith Hospital, London, UK
- Consultant, Institute of Cancer Research, London, UK
Academic & Research Contributions
- Moore, H. E., Davenport, E. L., Smith, E. M., Muralikrishnan, S., Dunlop, A. S., Walker, B. A., ... & Davies, F. E. (2009). Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Molecular Cancer Therapeutics, 8(4), 762-770.
- Muralikrishnan, S., & Davies, F. (2010). Autophagy is a key myeloma survival pathway that can be manipulated therapeutically to enhance apoptosis. Blood, 116(21), 408.
- Srikanth, M., Jenner, M., Wu, P., & Morgan, G. J. (2008). Survival and outcome of blastoid variant myeloma following treatment with DT-PACE. British Journal of Haematology, 141(s1), 20-21.
- Srikanth, M., & Davies, F. E. (2011). Targeted therapies in multiple myeloma. Oncology, 25(1), 34-42.
Awards & Recognitions
- GCRF Fellowship awarded by Royal Marsden Hospital, UK for research on Multiple Myeloma
- Member, American Society of Hematology (ASH)
- Member, British Society for Haematology (BSH)
- Member, European Hematology Association (EHA)














